FELIQS plans to conduct a Phase 1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in the first quarter of 2025.

Don't miss out on the headlines from Lifestyle. Followed categories will be added to My News. The study, the biggest of its ...

Metabolic dysfunction-associated steatohepatitis, or MASH, is a kind of chronic liver inflammation and scarring caused by ...

While babies born at full term after a gestation period of nine months weigh around 2.5 to 4 kg, this one was weak with ...

Oak Hill Bio and Chiesi Group have enrolled the first European patient in a Phase IIb clinical study for their collaborative ...

Oak Hill Bio, Chiesi announce first European patient enrolled in phase 2b study of OHB-607 for prevention of BPD in premature infants: Parma, Italy Tuesday, November 5, 2024, 14:0 ...

A woman who started a prematurity awareness day after her twin grandchildren were born 15 weeks early is set to host the event for the fifth time ...

A woman who started a prematurity awareness day after her twin grandchildren were born 15 weeks early is set to host the event for the fifth time ...

A woman who started a prematurity awareness day after her twin grandchildren were born 15 weeks early is set to host the ...

FELIQS®, a clinical stage multinational biopharmaceutical company focused on the development of first-in-class small molecules targeting lipid oxidation, announced today that the U.S. Food and Drug ...

El Mirage organizes a Community Blood Drive on November 12, 2024, supporting premature babies during National Prematurity ...

Now, due to state-of-the-art technology, advanced facilities, and expertise, the survival rates of premature babies have gone ...